<SEC-DOCUMENT>0001193125-13-479855.txt : 20131220
<SEC-HEADER>0001193125-13-479855.hdr.sgml : 20131220
<ACCEPTANCE-DATETIME>20131220060530
ACCESSION NUMBER:		0001193125-13-479855
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20131220
FILED AS OF DATE:		20131220
DATE AS OF CHANGE:		20131220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		131289733

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d647940d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of December, 2013 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">annual report to security holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to
furnish a report or other </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 20&nbsp;December 2013 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOVOGEN LIMITED</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(NASDAQ:
NVGN)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g647940g36s44.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20&nbsp;December 2013 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Novogen Announces Establishment of
Global Collaboration to Drive The Development of Drugs to Treat Brain Cancer </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20&nbsp;December 2013, Sydney, Australia: </B>Novogen Limited, an
oncology drug development company, announced today the signing of a Sponsored Research Agreement with Cornell University. The Weill Cornell Medical College (WCMC) in New York will become the cornerstone of a collaboration across Europe, US, Asia and
Australia involving universities and biotechnology companies seeking a treatment capable of delivering long-term remission for the main form of primary brain cancer, glioblastoma multiforme (GBM). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The research program is focused on the super-benzopyran drug, Trilexium (Trx). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The brain cancer program parallels that of the Company&#146;s efforts in the area of ovarian cancer through its joint venture, CanTx Inc, with Yale
University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CanTx has identified a Trilexium derivative (Trx-1) as having equipotent killing ability of both ovarian cancer stem cells and ovarian cancer
somatic cells, raising the prospect for the first time of being able with the one agent to kill the full hierarchy of cells within an ovarian cancer. The CanTx strategy is to bring Trx-1 into the clinic in the near-term as a generic treatment for
late-stage ovarian cancer, but then to use the Trx pharmacophore to create a panel of drugs capable of killing ovarian cancer cells with specific genotypes, a further unique feature of this technology platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The brain cancer program has the same R&amp;D and commercial objectives. The near-term goal is to bring Trilexium into the clinic as a generic treatment for
GBM that has failed to respond to Temozolomide, the only drug approved for GBM. The longer-term goal is to identify a panel of drugs capable of providing a personalized approach to GBM chemotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The program is based on the high potency of Trilexium against GBM cells, with both GBM stem cells and somatic cells being killed at equivalent dosages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVOGEN LTD &#150; ACN 063 259 754 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16-20 Edgeworth David Ave, Hornsby, NSW, 2077 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">P: +61 (0) 2 9476 0344 - F: +61 (0) 2 9476 0388 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.novogen.com </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Progression of GBM following radiotherapy and chemotherapy is believed to result from the regrowth of cancer stem
cells that are chemo-resistant. Recurrent tumor cells, like their parent GBM stem cells, are highly drug-resistant and with increased aggression, accounting for the poor prognosis associated with GBM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr David Brown, Novogen Group CSO, said, &#147;The collaborative effort to date has focused on bringing Trilexium into the clinic for the treatment of GBM,
and that goal will continue with the aim of bringing that agent into the clinic in early 2015.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The expansion of the collaboration to include
Cornell takes the program to the next level, which is to achieve personalized chemotherapy for patients with GBM. The objective is to identify a panel of Trx analogs that target individual GBM mutations within the genotype spectrum that
characterises GBM malignancies. That data then will inform our clinical objective which is to match the best drug candidate to an individual tumor genotype.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;WCMC has particular skills in identifying the genotype of explants from fresh biopsies of GBM tumors. We will be utilizing this ability to screen
Trilexium analogs for activity against a wide range of individual tumors,&#148; Dr Brown added. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Glioblastoma </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Glioblastoma multiforme is the most common and aggressive form of primary brain tumor. Worldwide, in developed countries, an estimated 3.5 cases per 100,000
people are diagnosed per year. Glioblastoma is one of the cancers most resistant to treatments and is associated with extremely poor prognosis. Despite therapeutic intervention (surgery/radiation/chemotherapy), glioblastoma remains a devastating
disease with a median 2-year survival rate in the range of 10&#150;25%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd is a public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange (&#145;NRT&#146;) and NASDAQ
(&#145;NVGN&#146;). The Company is based in Sydney, Australia, and with a US office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer
stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer and neuroblastoma. Novogen has entered into
a joint venture with Yale University known as CanTx Inc with the aim of developing personalized chemotherapy for patients with ovarian cancer. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Further information </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact Dr Graham Kelly, Chief Executive Officer. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: 61 2 9476
0344 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fax: 61 2 9476 0388 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mobile: (61)&nbsp;0429 854 390
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16-20 Edgeworth David Ave, Hornsby, NSW, 2077, AUSTRALIA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PO Box 2333 Hornsby Westfield, NSW, 1635, AUSTRALIA </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email:
<U>Graham.Kelly@novogen.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information is available on the Company&#146;s web site, <U>www.novogen.com</U> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVOGEN LTD &#150; ACN 063 259 754 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16-20 Edgeworth David Ave, Hornsby, NSW, 2077 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">P: +61 (0) 2 9476 0344 - F: +61 (0) 2 9476 0388 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.novogen.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g647940g36s44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g647940g36s44.jpg
M_]C_X0O117AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``"OR````G$``*_(```"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q,SHQ,CHQ.2`P-CHQ-3HS,@```Z`!
M``,````!``$``*`"``0````!```!`:`#``0````!````:``````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$```J;`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`00"@`P$B``(1
M`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]5226;]8.L5=%Z3?GO`<
M]@VT5G\^UWMIK_S_`*?_``:1-"RF,3*0B!9D:#I)+RT?XP_K1P78OF?1=_Z6
M7=?57KO[<Z2S*L#6Y51-.76V8%C?SF;O\':PLM9_74<,T)FHEGS<GFPQ$I@<
M-UH;=A)))2-=22222E))))*4DDDDI22222E))))*4DDDDI22222G_]#U5<-_
MC.Q<UU&#EM<78-+W,MK'#;;!MHR'_P`GZ='N_F_5_P"$7<JMU'"Q<_`OP\P`
MX]["RR8$`CZ8)^BYGTV/39QXHF/<,O+Y?:RQR5?"=?)\275?4.]_3?VEUBYS
MATZIC,=];0'.NR-P=4VH2/TE%=GI_P#H1_P:`WH?U4+01U?,=/#OL^A_E?S/
MYRN=0.+5A=.Z=T[<>F4U&^JUX(==<7/JR+;`?\)COW[V?F/O_<]-1<ORF2.0
M&>@;'Q'XQR\N6G'!(9)RH?W?ZSTCOKUTIH)./E::F*V_^E%T%-M=]3+JG!]5
MK0]CQP6N&YKA_97EPT,CLND^K'7L;I_3K*.H/]/&IN]+%LASB2YIOMQPRMKW
M_JWTM_T-EU5:NSQ`"XN)R_-RE+AR4!6A^6O-[!)9./\`6GH63D5XU.3-MSME
M8-=C071.W>^MK%I7WTX]+[\BQM--8W666$-:T#\Y[W>UJB((W%-R,XRUB1+^
MZ;2)(;\C'90<E]K&XX;O-Q<`P,C=ZGJ?0V;?SDV3EXN)2<C*NKHH;&ZVUP8P
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M-5:(.B=>(&[IUH=W`-9`/>/TBADU68>/]AN;Z>5DEM^968)94PG[#B.+2YOZ
M2SU,N_\`L5JT2#L7)C&4;,HD1`UO3B_JK.P;P"1?@SVW9E4?VDLV*\C[(PGT
ML#=CLW`M<Y\[\O)>R7;7Y5_O_P#"_H*L6M((<T$'0@CD%7&X^5U"IMN-4_)R
ML<-HS&,U>YH!^P9GNV[M]+'8M_N^G0QZ1T-DZ*%2!$0>+_&XH]FH0YP@.+3H
M6N'+7`[F/;_*8_W+J.M=3?U#_%_E9UC`+#3%C7-ECG,>UED-=[7TVN9_F+%H
MZ#UC)OKQW8EV.RUP:^]P:`QG^$L^G]+9_-_\(NQZUT49_P!7[^C8CFXPLJ%-
M3G`N:P-+=OM!#OHM468@T-RV^1A,&1(,8U5$5<GGNIO.!T#ZQ?5RTC;BX=V3
MTT&-<*UK]E31N=_R?D>IB?\`$?9/WUI8V/1U7ZT9HSJVW5]'JQF8=+QN8U]S
M79%V7Z;O;Z[OT=%=G^#95_PEBM?6?H%O6<4#%N;C9;66T"QX+F.HR&>AEX]K
M&.9[+&^G:S_AZ*4_4.CYXS6=5Z/D,HSA4VC(JO:YU&16PN=4+FUN8^F^AUEG
MH9-?^D]*RNVM0M]S_K#TK`HZE@755"H=6M?TSJ-50#1?3=1D/:ZX!ONMQK*&
M/JM_G/3]2OZ"'3UC,9]2FUA_^66N_8[3NU^V"S]FMNW?^SW_`!2T\/I'4[^I
M4]5ZWD566XC7-PL/%:YM%3K`679-C[2;<G)?3^A9N]*JBKU?T.^WU%!OU<L'
M7SGFUGV#UOMS<79[_MAI'3C:;)V>C]F]^S9O^TO]1)32Z!T;`LZKFBZH6U]#
M-73NF4V@.;36VC'R+KZV'V_:<NR_]+D_SOI55,0_K%L^KW4Z^I]+K91;EXN8
M,NIHVLM=C469V)?96R&.NILK?7ZNWU/2O]-:F;TCJ-/4K>J]$NJJORF,9F8V
M2TNIN-?MHO\`4JVW8^356?2W_I:[:O3WU?HF)8?1<N[-_:77;:<K)%3Z*,>E
MA%%-=L?:-GK.LLOMR&L8VVZST_T?Z)E22F/1^@]%Q^BU^OCTY!OI%N=DWM;8
MZ][V^ID7Y-MV]UGJ.<]WO]C&>S^;67G78+?K3CY%6$>IXK^DCT*\6NNT"LW-
M=7:SU'5U^AL^AZ:N,Z+]9.GXIZ9TW+Q;^F;#70,QEANIK(V-H]2FS9E5TM_F
MO4;39L_1^HFK^KG5\"_`OZ9DXSGX?3J^FO\`M%;R'"LM=ZS&TVLV;]G\VDIJ
M=;P\?JW[!Q!BOZ;7E6Y094^MC+:+!CY%M.0RNISV5WU7ULR*W,L3MZE;U(_5
MU^4T,S\;J5N-GUB(9D58N8R[;S^CM_I%'_=>VI:HZ7U;)RNF9G4;L?UNGWW6
M/;CL>UKV64V8U36^K98YMC/5WV*.5]7;+/K#C]5Q[FUT"QMV70YI)?;55=AT
M7TNW;:['49/H9'M]]5-"2G<22224_P#_TO54DDDE*7-_7/I;K\9G4J&%UV+[
M;FM!+G4N/NAK07.=0_\`3-_ZZND21C(Q((69,8R0,#U?+"VT`DTW&.PILD_#
MV+OOJWTH],Z:UMH`RKSZN2?![AI7_5I9MJ6JDGSR&0JJ8<'*QQ2,KXC5#392
M222C;*DDDDE*22224I))))2DDDDE*22224I))))3_]/U5)?*J22GZJ27RJDD
MI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JD
ME\JI)*?JI)?*J22G_]G_[1/^4&AO=&]S:&]P(#,N,``X0DE-!"4``````!``
M````````````````````.$))300Z``````$7````$`````$```````MP<FEN
M=$]U='!U=`````4`````4'-T4V)O;VP!`````$EN=&5E;G5M`````$EN=&4`
M````0VQR;0````]P<FEN=%-I>'1E96Y":71B;V]L``````MP<FEN=&5R3F%M
M951%6%0````:`%P`7`!S`&X`9P!F`&(`=0`M`&T`=P!S`"T`9@!P`#$`,`!<
M`$(`4P!)`%\`4`!2`#,```````]P<FEN=%!R;V]F4V5T=7!/8FIC````#`!0
M`'(`;P!O`&8`(`!3`&4`=`!U`'````````IP<F]O9E-E='5P`````0````!"
M;'1N96YU;0````QB=6EL=&EN4')O;V8````)<')O;V9#35E+`#A"24T$.P``
M```"+0```!`````!```````2<')I;G1/=71P=71/<'1I;VYS````%P````!#
M<'1N8F]O;```````0VQB<F)O;VP``````%)G<TUB;V]L``````!#<FY#8F]O
M;```````0VYT0V)O;VP``````$QB;'-B;V]L``````!.9W1V8F]O;```````
M16UL1&)O;VP``````$EN=')B;V]L``````!"8VMG3V)J8P````$```````!2
M1T)#`````P````!29"`@9&]U8D!OX````````````$=R;B!D;W5B0&_@````
M````````0FP@(&1O=6)`;^````````````!"<F1456YT1B-2;'0`````````
M``````!";&0@56YT1B-2;'0```````````````!2<VQT56YT1B-0>&Q`4@``
M``````````IV96-T;W)$871A8F]O;`$`````4&=0<V5N=6T`````4&=0<P``
M``!09U!#`````$QE9G15;G1&(U)L=````````````````%1O<"!5;G1&(U)L
M=````````````````%-C;"!5;G1&(U!R8T!9````````````$&-R;W!7:&5N
M4')I;G1I;F=B;V]L``````YC<F]P4F5C=$)O='1O;6QO;F<`````````#&-R
M;W!296-T3&5F=&QO;F<`````````#6-R;W!296-T4FEG:'1L;VYG````````
M``MC<F]P4F5C=%1O<&QO;F<``````#A"24T#[0``````$`!(`````0`"`$@`
M```!``(X0DE-!"8```````X`````````````/X```#A"24T$#0``````!```
M`'@X0DE-!!D```````0````>.$))30/S```````)```````````!`#A"24TG
M$```````"@`!``````````(X0DE-`_4``````$@`+V9F``$`;&9F``8`````
M``$`+V9F``$`H9F:``8```````$`,@````$`6@````8```````$`-0````$`
M+0````8```````$X0DE-`_@``````'```/__________________________
M__\#Z`````#_____________________________`^@`````____________
M_________________P/H`````/____________________________\#Z```
M.$))300````````"``$X0DE-!`(```````0`````.$))300P```````"`0$X
M0DE-!"T```````8``0````(X0DE-!`@``````!`````!```"0````D``````
M.$))300>```````$`````#A"24T$&@`````#20````8``````````````&@`
M``$!````"@!5`&X`=`!I`'0`;`!E`&0`+0`Q`````0``````````````````
M```````!``````````````$!````:``````````````````````!````````
M`````````````````!`````!````````;G5L;`````(````&8F]U;F1S3V)J
M8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO
M;F<``````````$)T;VUL;VYG````:`````!29VAT;&]N9P```0$````&<VQI
M8V5S5FQ,<P````%/8FIC`````0``````!7-L:6-E````$@````=S;&EC94E$
M;&]N9P`````````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T````,
M15-L:6-E3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N=6T````*
M15-L:6-E5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````````4F-T
M,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M
M;&]N9P```&@`````4F=H=&QO;F<```$!`````W5R;%1%6%0````!````````
M;G5L;%1%6%0````!````````37-G951%6%0````!```````&86QT5&%G5$58
M5`````$```````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$58
M5`````$```````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG;@``
M``=D969A=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N
M````!V1E9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L
M;W)4>7!E`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U
M='-E=&QO;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````"W)I9VAT
M3W5T<V5T;&]N9P``````.$))300H```````,`````C_P````````.$))3004
M```````$`````CA"24T$#``````*MP````$```"@````00```>```'G@```*
MFP`8``'_V/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@(
M"`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1
M$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`00"@
M`P$B``(1`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'
M"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&
M"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3
M\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2E
MM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%
M-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&
M%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U
M5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]5226;]8.L5=
M%Z3?GO`<]@VT5G\^UWMIK_S_`*?_``:1-"RF,3*0B!9D:#I)+RT?XP_K1P78
MOF?1=_Z67=?57KO[<Z2S*L#6Y51-.76V8%C?SF;O\':PLM9_74<,T)FHEGS<
MGFPQ$I@<-UH;=A)))2-=22222E))))*4DDDDI22222E))))*4DDDDI22222G
M_]#U5<-_C.Q<UU&#EM<78-+W,MK'#;;!MHR'_P`GZ='N_F_5_P"$7<JMU'"Q
M<_`OP\P`X]["RR8$`CZ8)^BYGTV/39QXHF/<,O+Y?:RQR5?"=?)\275?4.]_
M3?VEUBYSATZIC,=];0'.NR-P=4VH2/TE%=GI_P#H1_P:`WH?U4+01U?,=/#O
ML^A_E?S/YRN=0.+5A=.Z=T[<>F4U&^JUX(==<7/JR+;`?\)COW[V?F/O_<]-
M1<ORF2.0&>@;'Q'XQR\N6G'!(9)RH?W?ZSTCOKUTIH)./E::F*V_^E%T%-M=
M]3+JG!]5K0]CQP6N&YKA_97EPT,CLND^K'7L;I_3K*.H/]/&IN]+%LASB2YI
MOMQPRMKW_JWTM_T-EU5:NSQ`"XN)R_-RE+AR4!6A^6O-[!)9./\`6GH63D5X
MU.3-MSME8-=C071.W>^MK%I7WTX]+[\BQM--8W666$-:T#\Y[W>UJB((W%-R
M,XRUB1+^Z;2)(;\C'90<E]K&XX;O-Q<`P,C=ZGJ?0V;?SDV3EXN)2<C*NKHH
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M2YGO=[&9-5:(.B=>(&[IUH=W`-9`/>/TBADU68>/]AN;Z>5DEM^968)94PG[
M#B.+2YOZ2SU,N_\`L5JT2#L7)C&4;,HD1`UO3B_JK.P;P"1?@SVW9E4?VDLV
M*\C[(PGTL#=CLW`M<Y\[\O)>R7;7Y5_O_P#"_H*L6M((<T$'0@CD%7&X^5U"
MIMN-4_)RL<-HS&,U>YH!^P9GNV[M]+'8M_N^G0QZ1T-DZ*%2!$0>+_&XH]FH
M0YP@.+3H6N'+7`[F/;_*8_W+J.M=3?U#_%_E9UC`+#3%C7-ECG,>UED-=[7T
MVN9_F+%HZ#UC)OKQW8EV.RUP:^]P:`QG^$L^G]+9_-_\(NQZUT49_P!7[^C8
MCFXPLJ%-3G`N:P-+=OM!#OHM468@T-RV^1A,&1(,8U5$5<GGNIO.!T#ZQ?5R
MTC;BX=V3TT&-<*UK]E31N=_R?D>IB?\`$?9/WUI8V/1U7ZT9HSJVW5]'JQF8
M=+QN8U]S79%V7Z;O;Z[OT=%=G^#95_PEBM?6?H%O6<4#%N;C9;66T"QX+F.H
MR&>AEX]K&.9[+&^G:S_AZ*4_4.CYXS6=5Z/D,HSA4VC(JO:YU&16PN=4+FUN
M8^F^AUEGH9-?^D]*RNVM0M]S_K#TK`HZE@755"H=6M?TSJ-50#1?3=1D/:ZX
M!ONMQK*&/JM_G/3]2OZ"'3UC,9]2FUA_^66N_8[3NU^V"S]FMNW?^SW_`!2T
M\/I'4[^I4]5ZWD566XC7-PL/%:YM%3K`679-C[2;<G)?3^A9N]*JBKU?T.^W
MU%!OU<L'7SGFUGV#UOMS<79[_MAI'3C:;)V>C]F]^S9O^TO]1)32Z!T;`LZK
MFBZH6U]#-73NF4V@.;36VC'R+KZV'V_:<NR_]+D_SOI55,0_K%L^KW4Z^I]+
MK91;EXN8,NIHVLM=C469V)?96R&.NILK?7ZNWU/2O]-:F;TCJ-/4K>J]$NJJ
MORF,9F8V2TNIN-?MHO\`4JVW8^356?2W_I:[:O3WU?HF)8?1<N[-_:77;:<K
M)%3Z*,>EA%%-=L?:-GK.LLOMR&L8VVZST_T?Z)E22F/1^@]%Q^BU^OCTY!OI
M%N=DWM;8Z][V^ID7Y-MV]UGJ.<]WO]C&>S^;67G78+?K3CY%6$>IXK^DCT*\
M6NNT"LW-=7:SU'5U^AL^AZ:N,Z+]9.GXIZ9TW+Q;^F;#70,QEANIK(V-H]2F
MS9E5TM_FO4;39L_1^HFK^KG5\"_`OZ9DXSGX?3J^FO\`M%;R'"LM=ZS&TVLV
M;]G\VDIJ=;P\?JW[!Q!BOZ;7E6Y094^MC+:+!CY%M.0RNISV5WU7ULR*W,L3
MMZE;U(_5U^4T,S\;J5N-GUB(9D58N8R[;S^CM_I%'_=>VI:HZ7U;)RNF9G4;
ML?UNGWW6/;CL>UKV64V8U36^K98YMC/5WV*.5]7;+/K#C]5Q[FUT"QMV70YI
M)?;55=AT7TNW;:['49/H9'M]]5-"2G<22224_P#_TO54DDDE*7-_7/I;K\9G
M4J&%UV+[;FM!+G4N/NAK07.=0_\`3-_ZZND21C(Q((69,8R0,#U?+"VT`DTW
M&.PILD_#V+OOJWTH],Z:UMH`RKSZN2?![AI7_5I9MJ6JDGSR&0JJ8<'*QQ2,
MKXC5#392222C;*DDDDE*22224I))))2DDDDE*22224I))))3_]/U5)?*J22G
MZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27
MRJDDI^JDE\JI)*?JI)?*J22G_]D`.$))300A``````!5`````0$````/`$$`
M9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0
M`&@`;P!T`&\`<P!H`&\`<``@`$,`4P`V`````0`X0DE-!`8```````<`"```
M``$!`/_A#=9H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME
M="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^
M(#QX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L]
M(D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C`Q,B\P,B\P
M-BTQ-#HU-CHR-R`@("`@("`@(CX@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P
M.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M;G,C(CX@/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z>&UP/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+VUM+R(@>&UL;G,Z<W1%=G0](FAT='`Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(@>&UL
M;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN
M<SIP:&]T;W-H;W`](FAT='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N
M,"\B('AM<#I#<F5A=&]R5&]O;#TB061O8F4@4&AO=&]S:&]P($-3-B`H5VEN
M9&]W<RDB('AM<#I#<F5A=&5$871E/2(R,#$S+3$R+3$Y5#`V.C$U.C,R*S`X
M.C`P(B!X;7`Z365T861A=&%$871E/2(R,#$S+3$R+3$Y5#`V.C$U.C,R*S`X
M.C`P(B!X;7`Z36]D:69Y1&%T93TB,C`Q,RTQ,BTQ.50P-CHQ-3HS,BLP.#HP
M,"(@>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#HX-SE%13(W0S,Q-CA%,S$Q
M030Q14$T,#5#-3)!0S9!,2(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#HX
M-CE%13(W0S,Q-CA%,S$Q030Q14$T,#5#-3)!0S9!,2(@>&UP34TZ3W)I9VEN
M86Q$;V-U;65N=$E$/2)X;7`N9&ED.C@V.45%,C=#,S$V.$4S,3%!-#%%030P
M-4,U,D%#-D$Q(B!D8SIF;W)M870](FEM86=E+VIP96<B('!H;W1O<VAO<#I#
M;VQO<DUO9&4](C,B('!H;W1O<VAO<#I)0T-0<F]F:6QE/2)S4D="($E%0S8Q
M.38V+3(N,2(^(#QX;7!-33I(:7-T;W)Y/B`\<F1F.E-E<3X@/')D9CIL:2!S
M=$5V=#IA8W1I;VX](F-R96%T960B('-T179T.FEN<W1A;F-E240](GAM<"YI
M:60Z.#8Y144R-T,S,38X13,Q,4$T,45!-#`U0S4R04,V03$B('-T179T.G=H
M96X](C(P,3,M,3(M,3E4,#8Z,34Z,S(K,#@Z,#`B('-T179T.G-O9G1W87)E
M06=E;G0](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(B\^(#QR9&8Z
M;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP
M+FEI9#HX-SE%13(W0S,Q-CA%,S$Q030Q14$T,#5#-3)!0S9!,2(@<W1%=G0Z
M=VAE;CTB,C`Q,RTQ,BTQ.50P-CHQ-3HS,BLP.#HP,"(@<W1%=G0Z<V]F='=A
M<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RDB('-T179T
M.F-H86YG960](B\B+SX@/"]R9&8Z4V5Q/B`\+WAM<$U-.DAI<W1O<GD^(#PO
M<F1F.D1E<V-R:7!T:6]N/B`\+W)D9CI21$8^(#PO>#IX;7!M971A/B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#P_>'!A8VME="!E;F0](G<B/S[_X@Q824-#
M7U!23T9)3$4``0$```Q(3&EN;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q
M``!A8W-P35-&5`````!)14,@<U)'0@```````````````0``]M8``0````#3
M+4A0("``````````````````````````````````````````````````````
M`````````!%C<')T```!4````#-D97-C```!A````&QW='!T```!\````!1B
M:W!T```"!````!1R6%E:```"&````!1G6%E:```"+````!1B6%E:```"0```
M`!1D;6YD```"5````'!D;61D```"Q````(AV=65D```#3````(9V:65W```#
MU````"1L=6UI```#^````!1M96%S```$#````"1T96-H```$,`````QR5%)#
M```$/```"`QG5%)#```$/```"`QB5%)#```$/```"`QT97AT`````$-O<'ER
M:6=H="`H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P``
M```````2<U)'0B!)14,V,3DV-BTR+C$``````````````!)S4D="($E%0S8Q
M.38V+3(N,0``````````````````````````````````````````````````
M````````````````6%E:(````````/-1``$````!%LQ865H@````````````
M`````````%A96B````````!OH@``./4```.06%E:(````````&*9``"WA0``
M&-I865H@````````)*````^$``"VSV1E<V,`````````%DE%0R!H='1P.B\O
M=W=W+FEE8RYC:```````````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```
M``````````````````````````````````````````````````````````!D
M97-C`````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S
M<&%C92`M('-21T(``````````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````````````````````````
M9&5S8P`````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0``````````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$`````````````````````````````````
M`'9I97<``````!.D_@`47RX`$,\4``/MS``$$PL``UR>`````5A96B``````
M`$P)5@!0````5Q_G;65A<P`````````!`````````````````````````H\`
M```"<VEG(`````!#4E0@8W5R=@````````0`````!0`*``\`%``9`!X`(P`H
M`"T`,@`W`#L`0`!%`$H`3P!4`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`
MF@"?`*0`J0"N`+(`MP"\`,$`Q@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-
M`1,!&0$?`24!*P$R`3@!/@%%`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!
MJ0&Q`;D!P0')`=$!V0'A`>D!\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G
M`G$">@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#
M6@-F`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q
M!'X$C`2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%
MQ075!>4%]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]
M!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(
M^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<
M"O,+"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-
M#0TF#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>
M#WH/E@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2
M!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.
M%/`5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7
M]Q@;&$`891B*&*\8U1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[
M&V,;BANR&]H<`APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>
MZ1\3'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O
M(MTC"B,X(V8CE"/"(_`D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<F
MZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV
M*VDKG2O1+`4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O
M_C`U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38
M-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ
M-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B
M/^)`(T!D0*9`YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%
MFD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:
M2^),*DQR3+I-`DU*39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92
M,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+
M61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@
M!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]
M9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O
M'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X
M=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_
MA'_E@$>`J($*@6N!S8(P@I*"](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$
MB&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1
M/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IH
MFM6;0INOG!R<B9SWG62=TIY`GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D
M5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XM
MKJ&O%J^+L`"P=;#JL6"QUK)+LL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FX
MT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8
MP]3$4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.
MML\WS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQ
MVG;:^]N`W`7<BMT0W9;>'-ZBWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F
M#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_
M\HSS&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^
MW/]M____[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`!H`0$#`1$``A$!`Q$!_]T`!``A
M_\0!H@````8"`P$`````````````!P@&!00)`PH"`0`+`0``!@,!`0$`````
M```````&!00#!P((`0D`"@L0``(!`P0!`P,"`P,#`@8)=0$"`P01!1(&(0<3
M(@`(,11!,B,5"5%"%F$D,Q=2<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$
M5'-%1C='8RA55E<:LL+2XO)D@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI
M:G9W>'EZA8:'B(F*E)66EYB9FJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8
MV=KDY>;GZ.GJ]/7V]_CY^A$``@$#`@0$`P4$!`0&!@5M`0(#$00A$@4Q!@`B
M$T%1!S)A%'$(0H$CD152H6(6,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V
M160G"G.#DT9TPM+B\E5E=58WA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=7
M9CAVAI:FML;6YO9G=X>7I[?'U^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI
M^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#?X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]#?X]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?
M_]'?X]^Z]U[W[KW0#_)WY`[(^+/0W9W??85;#1[9ZWVKD\_/')-'%+DZVGIW
M_AF&HA(1YJ[*UQ2&)%NS,W`X]H=SW"#:["ZW"X/Z42%OF:#`'S/ET)^3.5=Q
MYVYGV;E?:XR;N\G5`:5"@GN<^BJ*DGKYSV[?YA_SO[*WAN_LRJ^5?<FT9=^[
MDRNY8-G[<W`U#MW:M#D:F27&X#$4*V2FI,?1%5L`+GWAON_NES/>;A=36MZ8
MX"YTA2P%*_;3KL=L_P!W?VFVO:=OL)^4K6YN(8E1I'6K.P&6)^9J:GI/2_-S
MYW+%*]#\S.^A71^*JH3/NEW@6NHY4JJ5)T^DE/--$J2*>&1B/:*/W+YMBFAD
M?<6948$BK9'F./[.C"3V"]GY(YXOZD6:^(M*A<K7S'6^M_*G^;N/^=_P_P!@
M]IUM13IV;MR$;"[CPT;?Y1B]_P"W8DI*^KFBL/'%N*GC2OBMQIG('`]Y?\J;
M_#S'LMIN,35D*@/_`*8#)_/C3RKUR6][?;>X]L.?]VV#PF&UNQEMF/!H6-0`
M?Z!JA^SJR3V).HCZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_]+?X]^Z]U[W[KW6
MFK_PI+^8&?W3VIUS\%=OQY/%[-VUBL=W)VE-50ST5%O/)22E-G8:B:33%E<9
MA90*B9DNHF9D;]/O'[WPYBN;:SMMB@JL<M"Q]>-!PX``T(IW'Y'KHY]R/VYL
M3:[O[C7FB3<"QMX!Q\-?]$8^C-PIZ4/6L^VDK>/A-7J'T]?T]/\`M(]XO$8Z
MZ$D+0&/X/\O75["_^^O[<)HM:=>ZM^_D<_+W/?%_YT[0ZNDBR>2ZR^6U7!L#
M<&!QD$E8V+["I(PVUMY1TD8;PTX5Q3UTX`TTX%S[F[V4YCGLMVEV20L;6:E!
MQ`)P*?GQ]0?EUB9][SV[L.:/;>?F8!(]WVG]1'.-49_M(R?.HRH_BZ^@;[RP
MZY&]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_]/?X]^Z]U[W[KW6NY_PH9^#T_>W
MQSQGRAZZP?WW;GQD6LS&4@HJ<-D-T=2U=VW=B'93Y*B3"1EJVFC`8EM?]/<7
M>ZG*:\Q;#+<PH/KK=2P/F5&:5H30'-!DY'67GW1?=4\E\Z'E/<[C3L.[L%&H
MT6.XX(WRU_`?RZTD*6JIJ^""MHI@^/J:>*I@/Y<R@'B_]#<'_$>\,&5D+)*I
M#JU"/2GEUUJ(4L2K?I4_G\OEUG!'Y(4#EBW`51R6/]`HY/O>JJU(ZJ/Y];'_
M`/(1^-NU=E8/N'^:/WA2FAV+U?M_<NTNDSE8`B30X^!CO7>N-6I7PS3UM0/X
M92,IUB125-_>5?L3R1,Z#=9H*W=PX6*HX#@3^52,\#7KFI]_7WPLN6MFEY+A
MN]-I;1?4WI#9-!6*#CQ8T:GF#0CI\S/\QWYP[NW'N?>&*[URNSL!NG<&2S&V
M=FT>#QTE-M7;M1.W\)P\<LJ&65X:4`NS<DM[SJM^3]@A@A26R,DH45:IR?,]
M?/-?^_GN5=7UY<VF]"&T>1F2/0#H4GM7\ATSUGS]^>[4TJT'R5S9KE"S4@DP
M&*,4L].ZSI33+XQ>"K,?C?\`.EC[<?E#EMAK>R*(O')STE'OI[I5QS'4_P"D
M7K:,^#OR<QORP^/&S.SD:G@W5'3G;O8.'B=3)AMZX4"DS,$D0`:"*LFC^XA!
M'^:E6U_<0;_M+[1N,MOI/@-W(3YH>'[.'6<_MASM#SYRE8;P"!?*/#G7^&51
M0_DWQ#Y'HWGLDZD/KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z__]3?X]^Z]U[W[KW4')XR@S6-K\/E:2"O
MQF4HJG'Y"AJHDFIJNBK(7IZJFGBD#))#-#(RLI!!!]Z(#`J14$=.0S2V\T4\
M+E9D8,I&""#4$'U!ZU&^S_\`A.7TGC^RM^G"_..+K#;V;W'D]Q[9ZYRF-VV]
M=LS"YNJ>MI\,LM7EZ:HJ**G9R(':-+I]/</WWL/MV[W<VX6YF6)V)HJDBOVU
MX]9H[?\`W@XY;VZQV3?]LL9-X@@57>2X5&:@H&T$5%0/,](*N_X3K]0U-(8)
M_P"8_C8::7QP5<D>-VG&[T+RHM=$DG\<M%+/2ZT5SPI:_P"/;=O]W6U2XB>3
MZET5@=.@_LZ?G_O(MJ>%UBVS;8YM.&^J4T/D>'1I?YD>]MC],=9]!_RW>BT_
MA_6VP=C;8W3OBLHU$=+G,!BDC7;E+]W%>')MN++AJ^N>-G21IB#]/>5OMKRU
M'M5DMU%&%$0\)%/$4PS$>3'KCO\`>\]W]PYSWZ;;);HRW%])]7<N"2K!C6%%
M/!D44I3%*#JJ`+:_"Z;V0``*J*`%`'T`"CW*Y8?"HH!UA+YD^?7)25(*\$'Z
M@<_[`_@^ZDU(#97TZV0.K#?Y6?R2JN@OD[CNM\D]1)UW\CJV+;]11TZRU`Q7
M9-+$%P672EC)")E*>U-426LJC4?8/YZVOZ_;!N18"2+X?F/,?Y1U//W?N>).
M6.;HMCFU':]R(1@/PR_@<#Y\&^76UVVZ]K([QON7`))&[1R(V8QRO&Z&SHZF
MI#*ZG@@\@^X6\*7_`'TW[#UT#-Y9J:&[C!_TR_Y^N4.Z-M5$T5/!N+!35$[B
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MIJ-.U1ZEC0`=:-W8>ZLKWOV1OCN_L*.IJ=X=DYRISE1'+55"1X7#&1UP6`HX
M5=8X*7&T!"A5`%V]Y&;58Q;9ML5@L8\,@&OGURNYDWF[YFW[<]_OVU7=S*S'
MY`GM4?)1PZ2<FT=OS1203T3R03)+%-&:NJLT<RE'`_<X.DFW]#[5:O3!]>B0
MQ1L""@H>CC4,-1WW\3JK&2NV5[U^$<+9;$,"TV7W_P#%[-U#+DZ2:61S/D*K
M8%6SF-`&98D!^GL*NK;1S&B(:6]\.)^%9O+Y=X_GU+\93GCVZDC<Z^9N7@67
MS>6P8]WS)@:I_P!+3HJM-505<$-53N'IJF))Z=P.'AE4,A%OR!P?\?8H=7!-
M*4_R^?42`@@$=9[@\!U#&VF_`OS^3;@?GW744*LZ%EKFF<=>H3PZ,]T74)TM
MU5V%\PZI(FWEEI,ET/\`%?'5,9+5&^,S3-#OSL^CB=&1X-G8QS''*+:)D)!O
M[#FZL=TO[?9(6/T2`22GS`KVI_MCQ^74J<GK%RIRSNG/]P@.YLS6NW@\/%8?
MJW`'GX*_">&OHG\&VH8H56IRVXZRL<O-65TVXLJTU975$K5%952MY^7FJ'8_
MZWL0K!;4A4P(='R&>HW.X[F2['<[@LQJ>]N)R3Q]>I,%'D,)D,1N7:N9W#C=
MU[2RM#N+;.27<&3)ILUB)EJZ7R(TY6:"IT&)T-PRN?;<VWV,T5S:R62!F!((
M&<^75X=ZWBUG@NH-TG\6-@P[VP5-1Y_+K=<^&GR1PGRJ^/NQ>V,;+"F8K:`8
MG>F*0HLN%WGB`*+/T4L"G5`CUL;2P@@7BD4CWC]O.VR[5?S6DBT`-1]AX?YN
MNGGMQSA;\[\I[9O<;@W)0),/-95%&J/*I[A\CU7!_.'[M^977^Y_B-U?\+NT
ML5UIV/W+OW=^-BBS&W,=N"AWG4[5VI6;GHMH3BO1_L5SCX\TXD2S!I![*<U'
M0Y/EZ=6!_`_Y5X+YE?&3K[NK&!*/<%3%7[2[*VZQ"UFTNT=F5DNW]];=KX`B
M&FGI<U1O*B$<031GF_O8X=>!KT5SX3?(?NGLWYP?S,NL.R-[P9SK7HKLKKK#
M=48+^%4./_N?A<OL6CR^8IYLA"B3Y%:BOD:4O,Q*`V%A[T,UZ]YGHM4/R7^=
M7\S#MSM/:_P.WWM?XO\`PYZ7WCDNM,_\J=R;3@WKOSNOL';]4E/NG&]-[=R4
M38J@VQMR8&)\G46\TALIY"^]9/#AU[CPZ;.[]@?SA/@OM^N^0_6GRCQ/STZ[
MV%2IGNV/C_V?UU@=E[XS6RL6'J=QY'K3<>U(E1,_CL8CSI3RD>?1I`/T][R,
M^77LC[.G+<7\QK=^>^1W\L#Y)=6=A?=_`SYNX7<?3^\-C9'%4/WVUN\,C325
M>SJW(9=HUK,778_*AL74P$K%)+`Q_/OWH?+KU1U?W[WUOJA39O\`,6W-CNW/
MYE/RU[2[#^V^!/Q`;$])]9[0Q.%HUK-\=O;=BCJ=]93%9-XUR6<R64S.7H\3
M24J%E20EB``1[U7B:XZT33J-U1U[_-^^;V"H>]^QODQA_@%U_O2E&=ZQ^/\`
MUEU_@-]]@X;:62056`K.TMU;HC:!MQUV.ECEFI*<Z:9F*D`BWOV3U[I.2?)C
MYZ?RQ.[>KMJ?/+LC:ORB^&?=^\,=UMMGY-87:E-LSL+I[L3<$QAVYB^TL+C4
M7%U^V\W4`0QUT?$;FQ(L1[T`0>..O9!^71O_`.83\[>S^E]U]/\`Q4^'FP</
MW#\T?DDN0J^OL-G:MH-@=:;!Q`0;@[A[*KZ<L\.U\.)+01*;U<PTCCZ[)\AQ
MZ]T!4/P@_F^YG!S[@W!_-:HL#V/6I]__``#:O0>T&ZRQ>19?(F.IX*Z`9B?$
MPRG020'=1?\`/OU#Z]>ST(?SI[4^8/Q$_E1[Z[#W'W)M+/?*_8.V]K4N9[?V
MELNFQ.U\AG,EN_$XBIR^-V=61_;TL;T%=8Q%;:KD>_>7'KQ\^@ZVK\1_YJ>^
M=@[4W7C_`.:O68F7=^S-N[ABC;X^=>U'\/J,]A:/)LB%Z<^:.G>JLI;E@.??
MJ'UZ]GUQU)_F?=C_`#,^/WQF^)O7G2OR%H<-\B>Q^W=A=-9ON+*[,P]31;PW
M'EJ(TXJ:K;C1-08N/<&50:EA`$6JPX]^],]>-?+HY_\`+E^5V3^5WQZ@RV_8
M(L/WQU-NC.],?(C:?BBI*G;G;>Q:@8_/@X];24N/S"A*NE)55>.0Z;A3[\.M
M]`7\>/D/W?O+^:]\XOC[NG>L.4Z4ZLZ<Z5W+UULP8>CIIMNY[<U17IN"O;+Q
M**RO7(K$HT2$K';CW[-3Z=:\^K:_>^M]>]^Z]U[W[KW7O?NO=?_6W^/?NO=>
M]^Z]U0#_`#R]\=C4V*Z)ZQAQM12=-;QS]?E]V;AAE;P9;=F`4S[>VE7QBRI3
M?2I75Q*S:>;>Y']OH+5I[V=F!NU6@!_A/$_F<=8F?>EW+=X=LY?VN%&79II&
M=V%:-(GPH?+`[A]O5"<W,LB(=2<`E1]+6X_V%K>Y8B>1XE:5=+CAUA90#AUR
M^GO76^A9^.F[-Z;'^2/2F:ZXQ;;EWAG-WP;#GV4'5(-^;.W:!C=V[;R)E5X4
MQ[8R1I&DD!2(^KCV4;_';2[)=";('<7'&-ERIK]O0T]N[_==OYVV*3:8/%N9
M91"8O*:.7MDC8?PE>->'1A.S?BG\8MJ=L=J;8Q'\P7KG96,PN^LU34NPJ_86
M<SM;L$RS?<5&SJC.4-%/195L)42-$)8G8$#\?3V0[?S#NQL;6O+DDW8._4!J
M^8'SZDG?_;+VZM][W:`>ZEK:A9W_`$?"9C%FIC+`$'2214&G2#K?C=\;)J<P
M5/\`,OZOHZ>KFI:*HK!U?N4/3T];50TM0T3G'*L4S0RLJ.Q"HQ#$@#VI?F;=
MX1V<L2(YX48&IZ*E]MO;MF4'WBM:5%?T7X$T/EUB^9OEPG=N"Z;QV+.W^M?C
MYUSMO;'3.*5XGHMU;<W%CZ?+9;MM)J>22EK:W>==4N[2J695?02"+>U7+8^J
MM;B[N7U7$\I>0^8=<".GD%&/Y]$_NO)):[[8\MPVW@[)MMJD=LH^&1'`8W'S
M,Q.JOE6G19/8BZB_K&0K.IN50F[.IM9AR+G\>[:Y$B,HH9UX#K5/(]6R?R9.
MRM_[>^2^^^HMOXFKS/6.]MGOO7=\T3E<?LG<V*)I,;F'7_-I)N2)!2E!RS#5
M]?<>>X%K:2V-O?-VWP;(]:^7^7K)G[LF][K:\U;AL5O$TFU7$)>3TC9/A?TJ
MWP_/[>C5_P`UN22+YI_R@I(F9'7Y49ZS(Q5Q_OR,CR"/]Y]Q":U&.L["?+SZ
M9M@D?RX?YKFX^K)V_A7Q<_F=5==O_K.)5$&"V1\L]O4Z#>NUZ2&.U-0KV5AG
MAJH$`7R5,36'OW`_+KW"O0:=+9#.8GY"?\*`LGMEZB/<%",558>2DU&J3(0]
M&NU.T`3U^59!<6YO[T,5ZUYG[.CN_P`CJ@P-#_*X^)SX"*!%R6QZO+9F2$()
M*K<60SN4FS556E>7KIJNYE9O43]?>Q@=;'#JU/+0TU3BLG3UJ))1SX^LAJXY
M0&C>FEII$G20-Z2C1,00>+>]];ZTU^GNE-Q=Q?R:/FUC^O()DR7QJ^:?<_>7
MQTDI8M+8^OZA[#J-W?9;;DCU&""<T]3"5B(5KVL3;W4<#Z]:I2O5]6^?Y@NW
M<)_*BD^>.*F\M5G/CUC-P[5HZ>9'JJGL[=&,@VU@,/"#=GJUWW6QHT=B]D(_
M%_>R:"O7O(5ZIS^4GQWKOC;_`"JOY=74.[J>&>+LKYD="]C_`"6KZM?V,WO3
MLS<60WUE#GYY;71<KD8J5E<E6-(@-[#WXXIUK@.'6VO&B1HD<2)'%&BI&D:A
M41%`5$15`54518`<`>]]6ZJ+_GM8S;F0_E;?)^;<*0E\1A=IYK;T\BJ9J3=.
M/WQMR3!U-"Y&N.M2J-HRMFN;#Z^]'@>M'HJ7PTG_`(]_.$WWD-[2SS[JP7\M
MOXMT^QA7H1+#A\SC8J[=4M$9?4QJ\LY:H9>2_P"KZ>_#KWGUL.U-3#1TU15U
M,@BIZ6"6IGE:Y$<,$;2RR&P)LB*3Q[WUOJBK^:M\@^DOE'_*!^1G:'3.^:#?
M?7D^0Q.VX]Q8R"LAI)-P[8[)P.-R>,:/(4])4`TN7B$,C:=-KD$CWKB,=:XC
MJ5L7O/\`G,8WJ[KREV1\)_BOFL+2[`V+%@*S)?('<='49#%+@\1%!4UD,.WV
M2DJ9,;^X8@6"2>FY]^SZ=>STQ_SF:[<D^P/Y<62W+0TF$W9+\X_CQ5Y[&8RK
M>LHL7G)*ZEDR5'05SHDE334=:SI'(0I=5!MS[\:XZ\?+K!VA)_PW'_-:VUW=
MY'Q/Q:_F6OBNL.U@&DBP.R/E5MRE8[#WK7%C)#3GL3$+/13RG3KJ;?X>_>?7
ML@_+I4_%4?\`8[O^8\?^_!?'G_W*R?O?J.O>?5YGOW6^O>_=>Z][]U[KWOW7
MNO_7W^/?NO=>]^Z]T5KYE?&_#_*CX_;XZHKQ'3YFLH3EMEY=E'EP>\L2KU6!
MR,4FEG15K%"2!;:D8@^S;9=SDVJ_BN4:B<&_TIX_L\N@)[C\F6W/7*FX[),H
M^JTZX6\UE450U]"<$>8.>M+(193#UF6VSN>F&(W?M;,9#;&[,54,L,]#G<-.
MU-6))%(RNBRE`ZDBS`\>\B()?J[:*Z!!@"C/KC'7+R[M+FPO+FQNHRMU$[(P
M(-0RFA'6?RP?FHIP!R6,\0"@<EB=?``Y/OW^#IFA]#T<GXW5$?0?2O9GSAR=
M+&^]<N<ET3\2<?5(GDJ]T9R%J3=_8])%*KK-2X*&1H_(H]`B)!%Q["F[30[C
MN4'+\!*V8(DN2#\0'PI^9ZF3DF)>3N4MV]R9U'[WEU6FVAO]^.*37`!XB-<`
MXH<]$DHL>M/"?OI!DLE433UF5R4\<<E1D<K6RM4Y"NJ)75GEFJ*AR2Q))'L6
MJ'"+"B*L""BCY>5>H:<F21YI&+3.26)R2QR2?SZD34%!50S4L]'3R4]3%)3S
MQO!"=44R%'`]'!TGZ_@^]L945O#"^)Y'T^?5"B'XA5>C5NE3W_\`%<5\K293
MO;X/1+25A!:;*;_^+N?J&\-:2SF2JEZYKG90H#%88Q]![#;UV?>$D(_Q"_\`
M/R6<<?\`>Q_/J6F']=_;_P`=WU\R<O+0^;RV#G!/F3`]:^B4Z*[#/!4PQU-/
M(DM//%'/%(K*5DBE4,A'/Y!M_K^Q'IX&HSU$X((X]1*^NCQM!4ULUA!`C3&.
MX+RO=4@IXU'+25,[+&H%R2WO40'CSS.W:B?E7KS$Z0%XGK:V_E4?%B;X^_'N
MDWANZ@6'M;NEJ;>V[9)HP*K%8FJA5ML;:5B/)##C\4T;R1\#SNUQ<>X+YNWA
MMTW-U5JPQ8'S/F?\G717V'Y#3E#E&"_NHJ;SN"B60D95"*QI]E.XCU/0$_S0
MMA=B[L^7_P#*CS>S>OMV;PP.S_DSG,KO7.;?QK5N,V;B)-FY""/+;BJ`RBAH
M))V"!S>[&WL)UX#J<",UZ-C_`#,?B-+\P?B_G]J[6F_A/<W6F;PO<O06ZX#X
M<AMOMCKZJ7,X%J6J1#/%#FXX9:"9%91(M0-1LOOQX=>(J.B`?R@ZKMCM_NSY
M\=U]W_'_`'[TG7]X9+JNGW-MG?N`.'HLEN;;W7E'M/>JX$--,N1PM97T\KI(
M+!D?WX<>M#->@VZMS_R5_DI;][%Z<W%T/V=\E?Y=&\]^Y_L7I7LSIG%#=O8?
MQY;=]>^2W!USOC9ZR0UV4VQ0UKL]!40,`BD@"Q(.L@\,=;X?9T)7<7\S;Y`?
M,#;64Z%_EK_%/O2IWUV)0S;5S'R([ZV/4]5=3])8G-1O0YC=-7'F)9\EN7-X
MS&SO)1TL`374:>3;WZO"@Z]6M13JSSX6_#78OPZ^)NP_BSAZN7=V+P6WLE3;
MUW#EXPU5OO=6ZVJ*W?.X\E$Q)+;@RM=.^AB2L;*I/'NW6^M<OI[XW?(#.[_Z
MT_E-[HZ<[1QWQ]^/WS@WQ\B,_P!RY3$LO5^[/CY@LAD-W=4;#PV3,_BK:E]V
M5$.N`K9$C'`L;Z_S]5(..MC7YY_$';7S@^+'9'QSS64DVM5;DH*+)['W;11:
MJG9._MLU"979FYJ.)&CYQ65ITU*I!\+.!S;WL]6ZK`Z;_FG]W_%3:^,Z*_F5
M?%+O_"]K=>8^';%/WCTCL&O[8ZG[PHL*@H:#>.%J<5/%D,+D\S10)-54M0&T
MU#M8@<#5:8ZU7-*=(CL.J^2_\Z;??7'6#]`=F?%S^73L/?6`[,[1WKW%2C;?
M9OR4KMH5\>4VML+:FRTDDFPFRWRD,<]?4U3,\@32/P/>N/ECKV3T9?\`F&?#
M_P"0N$[DZ2_F"?`FBPN3^0WQZVU4]>;QZ.S-4V)VW\@NB:MUFJ^OUR2.HQ6X
ML*RM)BY6!760MQ;G=,U'7ND10?SN]FU."K]I=M?"/YQ]9=N3T%9B*[KA.EZO
M=,7\7GI)*?[>@W5CJNGQ=31SU+:8YRH&DAB/?J]:)].B%8;XZ]]T7_">/N/J
MZLZ(["PO:6Y^Q-W;TQ74;86(;\EPF9[@Q.Y:)_X/3RZ/O9L2C2%=5^#?WKRX
M=;.`!T?K8?\`-[Q&QNM]B[7JO@Q\\ZZMVEL':V%R#4O2#,CUV"V[0T59%3L<
MQ>8&>E8(W&KCZ7][J.O5QT@?YCV[=^?+KH/^7/VUUET)W32+D_FMTONW<&QM
MQ[1..WWL#;>.W`T.1S.]<**J3^$4%"L/DE?6P6,@^_5X<:=>\Q7JT[Y]?$S;
M_P`UOBKVIT)EY!C\WGL.,UUWN:(*E?L[L[;$J9S8FYL;4ED>CJ,?N"BA#R*P
M/A=Q^?>^M]5%?RC*CY!;[^;'R8[9[\Z-[*ZIWHOQ]Z7Z>W[G=YX=J+`;Y[!Z
MMR>6P>4W1M3)-/+_`!6BW'1TT5=K%O\`/^]#)P,=:!J3UL>^]];Z][]U[KWO
MW7NO>_=>Z__0W^/?NO=>]^Z]U[W[KW5?G;/\L/X=]T]E;F[9WOUS53;UWB]+
M-N2OQ6XLQB*?*5=)$8DKIZ&BJ8Z85LB']R0*&D/)]B?;^;MXVZT2S@D4P+PU
M+7\NH7YG]A^0N:M[O-_W"&Y2^GH7\.4HI;S;33#'S/GT&\_\F_X(U$,L$G7&
M>\<T;Q2!=[;C4F.12KJ&%:"-2FW'LT_UQ.8!_OC_`'@=!\_=C]MB"*7V?^'M
M_FZJ;_FQ]+;AZ4[%^/.W<#14V'^,>W-@U6R^G<!BXITQ^U=XT[-49^/,SR,_
MWV9S=$P>.HD)D<-:]_8IY*O[3<!=RW"ZMS:0M(?4'X:#R`X4ZA#[PG+&X<N7
M7+=I:1A>3H+;PK55!HCC,GB'\3O\6KS!ZK%75:S6N">1^>?S_4^QVU*D`YZQ
MQ'73WM8?4GZ>[1:?$77_`&?GUIJZ33CT;?\`E_[/W]OOYG=7X;KJ.F%+18G<
M+]RRY&F-5@ZOJ#*4C4&<VYF("#%+-GBS14H;E9?4.?86YHECMMDO'O&(R##_
M`*>O:1]GKU+'LKM^[;C[@;5#M2!H2CBYU90VS"DBOZZAA1Z\.KQ?^&5?A*DE
M2:7";^I*>>HJ9HZ.#?F:6GI4J9WG--3)Y+1P1,Y"*/TKQ[C.+G/?(0@65#I-
M<J.LMW^[E[8N6)VV<`DG^U;S->G'`_R9_A7@MR[8W,-O[UR<^U<Y0;@HL=E=
MZYBLQ-778R43T:9*ADE\5;2QSJ',;W5BHO[=N>>M_NDDC>9`K"F%`X]/67W>
M/;.QN[>[BVN5I(I`X#2L15345!XBN:=6MHB1HL<:JB(JHB(H5$10`JJH`"JH
M%@!P![!Q))J>/4X`!0%4`*!@=<O?NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7__1W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]T4W
MYL_&K&?*KX\[XZNF6"GW(]&<[L+,2(IDPF]<,K5>"K(Y=)DCBDJ4$<H4C4C\
M\#V;;)N<FU;A#<JQ\.M&'JIX_LX]`'W+Y-AYYY1W+92H^LTZX6QVRKE<^0;@
M?D>M*-]PT6$K,IMK=V1HL%O#:N5K]M[LPE;)]O5XS/XB9J6N@FADLRAG4,O%
MB&]Y$I-!<PPW$7=K4&O7+ZZM;FQNKFSNHBD\3E&%.#*:$=1ZO?6SZ&FJ*Z7<
M6+D2EB:4QI4J7D8<)#$H-VEGDTH@')9@/=A1@T8(35YGI,6]5;]G6UC_`"C_
M`(MU/2/0S=J;SH/!VCWN:7=>4%1#HJ\'L]HPVT]NC59XT%"5J94('[LO]?<(
M\Z[U)N6X_2!ZV]OVBG`MYG_)UT)^[YR)_5;E,;S?0:=XW*CFHRL7^AK^?QG[
M1U;+[!G4_P#7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U__TM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MT#V6^/?16>RV1SV:Z@ZXRF:S%2U;E<I7;/P=17Y&L?\`755M3)1-+4U#_P!I
MW)8_D^U27U[&H6.[D"CR#'_/T23<M<OW$DDT^R6KRNU6)B0DD\221D]-_P#L
MLWQXNI_T(]7'1)'*M]D[?(62%UEB<`T)&J.1`P_H1[L=QOSQO)?]Z/\`GZ;'
M*O+0X;#:?\XD_P`W0VQ11011P01QPPPQI%%#$BQQ111J$CCCC0!$C10`````
M/:0DDDDU/1ZJJBJB*`@%`!@`>@'63WKJW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U_]/?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
L?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
